Target intelligence / Profile preview

Potassium channel (gastrointestinal)

Molecular classification
Ion channel, Potassium channel (voltage-gated, calcium-activated, inwardly rectifying, two-pore domain), Transporter (if including K⁺ transporters like H⁺/K⁺-ATPase)
01

Overview

Potassium channels in the gastrointestinal tract are transmembrane proteins that control the flux of potassium ions across epithelial and smooth muscle cell membranes. They are essential for maintaining membrane potential, regulating iron and water transport, supporting acid secretion by gastric parietal cells, and determining smooth muscle excitability and contractility. Multiple families (voltage-gated, calcium-activated, inwardly rectifying, two-pore domain) are expressed throughout the GI tract. Dysregulation or mutation of GI potassium channels is linked to disorders including acid-peptic diseases, motility disturbances, inflammatory conditions, and GI cancers[1][3][5][8].

Other names
gastrointestinal potassium channelGI K⁺ channelpotassium ion channel (gastrointestinal)GI K⁺ transporter (if including transporters)
02

Mechanism of action

Blockade or modulation (activation/inhibition) of potassium channels to alter acid secretion, motility, or secretion/absorption processes; Inhibition of H⁺/K⁺-ATPase to suppress gastric acid secretion[1][3][5]

03

Biological functions

Maintenance of membrane potentialRegulation of fluid and electrolyte secretion and absorptionAcid secretion (in stomach)Epithelial transportSmooth muscle contractility and motilityCell volume regulationParticipation in cell proliferation and apoptosis
04

Disease associations

Peptic ulcer diseaseGastric acid disordersGastrointestinal motility disordersInflammatory bowel diseaseCancer (colorectal, gastric, pancreatic)Electrolyte imbalance syndromes
05

Safety considerations

Disturbance in potassium homeostasis leading to cardiac arrhythmias or muscle weakness if channels are inhibited systemicallyAltered GI electrolyte/fluid balance and acid-base disordersHypokalemia risks from excessive loss/inhibition
06

Interacting drugs

Potassium channel inhibitors (e.g., sulfonylureas)

3 more in the full profile.

07

Biomarkers

Expression of specific potassium channel isoforms (e.g., Kv1.3, Kv7.1) in GI epithelial or tumor cells as diagnostic/prognostic markers[2]Methylation status of potassium channel gene promoters (for cancer prognosis)[2]

Beyond the preview

Go deeper on Potassium channel (gastrointestinal).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium channel (gastrointestinal).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call